Fentanyl
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Fentanyl: From Opioid Analgesia to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Fentanyl is a potent opioid commonly used for pain management and anesthesia, though the detailed original indication text is not available in this evidence pack. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis, but currently no clinical trials and no literature support this direction — this is a model-only prediction at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current evidence pack (no licenses or indication text on file) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for fentanyl in this evidence pack. Based on general pharmacological knowledge, fentanyl is a synthetic mu-opioid receptor agonist widely used for moderate-to-severe pain control and as an anesthetic adjunct. This general classification is not itself derived from the evidence pack and should be independently verified before use in any regulatory or clinical context.
A plausible mechanistic rationale for the predicted indication is that opioid agonism can influence antidiuretic hormone (vasopressin/ADH) release and renal water handling, which is mechanistically adjacent to syndromes of inappropriate antidiuresis. However, this link is speculative at this stage — no clinical trial or literature evidence in the pack currently substantiates it, so it should be treated as a hypothesis generated by the model rather than an established pharmacological relationship.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
No marketing authorizations are currently registered in Germany for this product (0 authorizations on file).
Safety Considerations
Please refer to the package insert for safety information.
Note: The safety data gap for TFDA/BfArM label warnings and contraindications (DG001) is flagged as Blocking in this evidence pack — it prevents completion of the initial safety screening (S1) and must be resolved before any further development.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication currently rests on the TxGNN score alone (L5 evidence), with no supporting clinical trials or literature, no confirmed market presence in Germany, and a Blocking data gap on core safety/label information. There is insufficient basis to advance this candidate at this time.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain TFDA/BfArM label warnings and contraindications
- Resolve DG002 (High): obtain mechanism of action data from DrugBank to support or refute the mechanistic rationale
- Confirm original approved indication(s) and current market/license status
- Conduct a targeted literature and clinical trial search for fentanyl and nephrogenic syndrome of inappropriate antidiuresis (and secondarily, Tourette syndrome, TxGNN score 99.05%, rank 9710) before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.